tacrolimus topical / Generic mfg. - LARVOL DELTA

Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study. (PubMed, JAAD Int) - No abstract available

Journal • Medicare • Observational data • Reimbursement • US reimbursement • Atopic Dermatitis • Dermatitis • Dermatology • Vitiligo

Comparison of the Efficacy of Topical 0.05% Clobetasol Propionate and Topical 0.1% Tacrolimus in the Treatment of Early-Stage Mycosis Fungoides (EADV 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Comparative study between efficacy of Excimer light with topical Tacrolimus 0.1% versus excimer light with topical Bimatoprost 0.01% in treatment of facial Vitiligo (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Efficacy and safety of topical Methotrexate 0.5% gel versus topical Tacrolimus 0.1%ointment in treatment of non segmental vitiligo (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Effectiveness, safety and tolerability of tofacitinib 2% ointment vs tacrolimus 0.1% ointment in localised vitiligo : Investigator Blind, Randomized Controlled Trial (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Topical Tofacitinib versus Topical Tacrolimus for Mild to Moderate Pediatric Facial Atopic Dermatitis in Skin of Colour: A Randomized Non-inferiority Study (EADV 2026) - No abstract available

Clinical • Head-to-Head • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Efficacy of probiotics combined with tacrolimus ointment in children with atopic dermatitis and its effects on serum IgE, IL-4, and LTB4: A single-center retrospective cohort study. (PubMed, Medicine (Baltimore)) - "The incremental 5.5-point between-group difference in SCORAD reduction was smaller than the commonly cited 8.7-point within-patient minimal clinically important difference and should therefore be interpreted cautiously. Prospective randomized studies with longer follow-up are required."

Journal • Retrospective data • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Food Hypersensitivity • Immunology • IL4

3-year longitudinal outcomes after the world's first human whole eye transplant (TTS 2026) - "During 18-mo follow-up, the patient experienced a mechanical corneal abrasion that resolved with topical tacrolimus and antibiotics to the transplanted eye resulting in near-complete healing with minimal residual corneal scarring...The patient remains on stable maintenance immunosuppression consisting of tacrolimus, mycophenolate, and prednisone... 3-year follow-up of the first partial face and WET demonstrates long-term ocular graft survival with stable but attenuated retinal architecture, decreased, but stable ERG activity, without evidence of rejection. Although visual function has not been restored, exceptional aesthetic and sustained biologic viability of the transplanted eye represent a milestone toward the development of ocular transplantation. Longitudinal healing of mechanical corneal abrasion Immunosuppression regimen"

Corneal Abrasion • Inflammation • Mood Disorders • Ocular Inflammation • Ophthalmology • Transplantation

The role of the alpha-gal antigen in corneal xenotransplant rejection: a review. (PubMed, Arq Bras Oftalmol) - "In addition, it evaluates five major mitigation strategies: GGTA1-knockout pigs, enzymatic α-galactosidase treatment, RNA interference, decellularization, and immunosuppressive approaches, including CD40-CD154 blockade and topical tacrolimus. Preclinical studies have demonstrated that GTKO corneas can maintain transparency for longer than 1 year, whereas decellularized matrices preserve corneal architecture while exhibiting low antigenicity. These findings support the future clinical translation of porcine corneal xenotransplantation."

Journal • Review • Immunology • Ophthalmology • Transplant Rejection • Transplantation • CD40 • CD40LG

The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort. (PubMed, JGH Open) - "Topical tacrolimus was used in 10 patients, of whom three achieved treatment success...Despite a short segment of inflammation, UP remains a clinical conundrum as many patients develop refractory disease, disease extension, and complications. Further prospective studies are required to define optimal therapeutic strategies for this under-recognized cohort."

Journal • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Ulcerative proctitis

Dupilumab-Induced Vitiligo Managed Effectively With Nemolizumab and Targeted Topical Therapy. (PubMed, Cureus) - "The patient was subsequently switched to nemolizumab, an IL-31 receptor antagonist, and treated with topical tacrolimus 0.1% ointment on one hand and ruxolitinib cream on the contralateral hand to compare treatment efficacy. The superior efficacy of topical JAK-STAT inhibition with ruxolitinib compared to tacrolimus suggests JAK pathway modulation may be more effective for managing biologic-induced pigmentary disorders. Clinicians should monitor for the development of vitiligo in dupilumab-treated patients."

Journal • Dermatology • Immunology • Vitiligo • IL13 • IL4

Esophageal Involvement in Bullous Pemphigoid: A Rare Case Report (ACG 2026) - "Dupilumab was selected after failure of first line therapies including topical and low-dose oral corticosteroids as well as topical tacrolimus...He was discharged on a prednisone taper, topical corticosteroids, doxycycline, and dupilumab...Figure: Esophageal mucosal bleb seen on esophagogastroduodenoscopy. Figure: Mid-esophageal plaque seen on esophagogastroduodenoscopy."

Case report • Clinical • Bullous Pemphigoid • CNS Disorders • Dermatology • Dermatopathology • Gastrointestinal Disorder • Immunology • Multiple Sclerosis • Urticaria

AQUA: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (clinicaltrials.gov) - P3 | N=464 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tofacitinib for Calcinosis Cutis Associated With Juvenile Dermatomyositis: An Open-Label Single-Arm Study. (PubMed, ACR Open Rheumatol) - "Tofacitinib, when added to standard therapy, reduced the Agatston score in children with CC associated with JDM. No major safety signals were observed during the study period. Clinical Trials Registry - India: CTRI/2024/02/062740."

Journal • Dermatomyositis • Hematological Disorders • Immunology • Infectious Disease • Metabolic Disorders • Myositis • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Tuberculosis • IFNA1 • IFNB1

Tranilast/roxithromycin with topical tacrolimus in refractory atopic facial eczema: Case report. (PubMed, Int J Clin Pharmacol Ther) - "Within 3 weeks, his eczematous lesions on the face, as well as the severe itching, were completely cured. Addition of this combination therapy may be a promising therapeutic strategy for treating uncontrollable atopic dermatitis, particularly for facial eczema and itching."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Atypical Orogenital Lichen Planus in a Young Male: A Case Report. (PubMed, Clin Med Insights Case Rep) - "The patient did not respond to topical corticosteroids but did improve slightly with topical tacrolimus 0.1%. This case demonstrates a unique presentation of lichen planus in a young male, with genital-to-oral development and diagnostic confusion in the absence of biopsy. It highlights the need for clinically identifying non-venereal dermatoses in genital lesions and the impact of psychological factors on treatment and diagnosis choices."

Journal • CNS Disorders • Dermatology • Dermatopathology • Lichen Planus • Pain

Vitiligo Masked by Steroid-Induced Rosacea-Like Dermatitis and Revealed by VISIA Ultraviolet Imaging: A Longitudinal Case Report. (PubMed, Cureus) - "Following corticosteroid withdrawal, topical tacrolimus 0.1% ointment was initiated. This case highlights how persistent facial erythema can mask progressive depigmentation and demonstrates the value of multimodal VISIA imaging, particularly red-channel and ultraviolet modalities, in detecting subclinical pigmentary changes, differentiating overlapping disease processes, and documenting disease progression."

Journal • Dermatitis • Dermatology • Immunology • Mood Disorders • Rosacea • Type 1 Gaucher Disease • Vitiligo

Ritlecitinib with concomitant phototherapy and/or topical tacrolimus in children with active, treatment-refractory vitiligo: a retrospective cohort study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Dermatology • Immunology • Pediatrics • Vitiligo

BRAFV600E-Mutant Non-Langerhans Cell Histiocytosis Clonally Related to Remitted Acute Myeloid Leukemia. (PubMed, J Cutan Pathol) - "Work up demonstrated isolated cutaneous involvement without AML relapse; therefore, the skin lesions were treated with shave excision, topical tacrolimus 0.1% ointment, and topical clobetasol 0.05% cream without further systemic treatment. The acquired BRAF V600E mutation illustrates the potential for divergent myeloid differentiation and likely explains the emergence of a clonal NLCH after successful AML treatment. Genetic analysis in NLCH can establish clonality with associated hematologic malignancies, uncover actionable mutations, and guide treatment."

Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Langerhans Cell Histiocytosis • Leukemia • Oncology • Transplantation • BCOR • BRAF • CCND1 • CD163 • CD1a • CD20 • CD68 • DNMT3A • F13A1 • IDH1 • KMT2A • TP53

Tacrolimus Ointment as a Hidden Source of Beeswax Exposure in Allergic Contact Dermatitis: Report of Two Cases. (PubMed, Contact Dermatitis) - No abstract available

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Isolated Sclerodactyly Associated with Silica Exposure in a Stonemason: A Case Report. (PubMed, Case Rep Dermatol) - "Dermatitis improved with exposure cessation and topical tacrolimus therapy, while sclerodactyly persisted...In this case, it permitted earlier detection and management of silicosis. Given the potential for progression to SSc, early identification and multidisciplinary surveillance may help prevent progression and associated morbidity."

Journal • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Fibrosis • Immunology • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

Clinical Assessment of Protopic Ointment in Deep Partial-Thickness Burns (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Vanderbilt University Medical Center | N=18 ➔ 1 | Trial completion date: Jun 2028 ➔ Apr 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2027 ➔ Jan 2026; PI departure from institution

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Azithromycin in Atopic Dermatitis (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Cairo University

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Response to Topal and Yılmaz, "Considerations Regarding Lesion-Level Analysis and Treatment Heterogeneity in Pediatric Vitiligo". (PubMed, J Am Acad Dermatol) - No abstract available

Heterogeneity • Journal • Dermatology • Immunology • Pediatrics • Vitiligo

A Systematic Review of the Clinical Application of Topical Tacrolimus in Vascularized Composite Allotransplantation. (PubMed, Plast Reconstr Surg Glob Open) - "This systematic review highlights the potential role that TT may play in mitigating the need for increased doses of SI during AR episodes. As clinical data continue to grow, further research is essential to establish the potential benefits and efficacy of TT use in VCA."

Journal • Transplant Rejection • Transplantation